Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease
- 19 August 1998
- journal article
- clinical trial
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 9 (5) , 246-257
- https://doi.org/10.1159/000017069
Abstract
Nerve growth factor (NGF) is important for the survival and maintenance of central cholinergic neurons, a signalling system impaired in Alzheimer’s disease. We have treated 3 patients with Alzheimer’s disease with a total of 6.6 mg NGF administered continuously into the lateral cerebral ventricle for 3 months in the first 2 patients and a total of 0.55 mg for 3 shorter periods in the third patient. The patients were extensively evaluated with clinical, neuropsychological, neurophysiological and neuroradiological techniques. Three months after the NGF treatment ended, a significant increase in nicotine binding was found in several brain areas in the first 2 patients and in the hippocampus in the third patient as studied by positron emission tomography. A clear cognitive amelioration could not be demonstrated, although a few neuropsychology tests showed slight improvements. The amount of slow-wave cortical activity as studied by electroencephalography was reduced in the first 2 patients. Two negative side effects occurred with NGF treatment: first, a dull, constant back pain was observed in all 3 patients, which in 1 patient was aggravated by axial loading resulting in sharp, shooting pain of short duration. When stopping the NGF infusion, the pain disappeared within a couple of days. Reducing the dose of NGF lessened the pain. Secondly, a marked weight reduction during the infusion with a clear weight gain after ending the infusion was seen in the first 2 patients. We conclude from this limited trial that, while long-term intracerebroventricular NGF administration may cause certain potentially beneficial effects, the intraventricular route of administration is also associated with negative side effects that appear to outweigh the positive effects of the present protocol. Alternative routes of administration, and/or lower doses of NGF, perhaps combined with low doses of other neurotrophic factors, may shift this balance in favor of positive effects.Keywords
This publication has 12 references indexed in Scilit:
- NGF and the Treatment of Alzheimer's DiseaseExperimental Neurology, 1993
- Nerve growth factor and nociceptionTrends in Neurosciences, 1993
- Tacrine restores cholinergic nicotinic receptors and glucose metabolism in alzheimer patients as visualized by positron emission tomographyNeurobiology of Aging, 1992
- Sensitivity of Fischer 344 × Brown Norway hybrid rats to exogenous NGF: Weight loss correlates with stimulation of striatal choline acetyltransferaseNeuroscience Letters, 1992
- Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseasesNeurobiology of Aging, 1989
- Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factorNature, 1987
- Sample handling techniques when analyzing regulatory peptidesLife Sciences, 1987
- Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brainsNeuroscience Letters, 1986
- “Mini-mental state”Journal of Psychiatric Research, 1975
- The action of ouabain on the chronotropic effects of sympathetic nerve stimulation and isoproterenolEuropean Journal of Pharmacology, 1970